CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company developing proprietary CRAC channel inhibitor therapies — including IV candidate Auxora and oral candidate CM5480 — for acute and chronic inflammatory, immunologic, and cardiopulmonary diseases with no approved disease-modifying treatments.
- Company typePublic
- Founded2007
- HeadquartersLa Jolla, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CalciMedica does
CalciMedica is a clinical-stage biopharmaceutical company developing small-molecule CRAC (Calcium Release-Activated Calcium) channel inhibitors for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its pipeline centers on two drug candidates: Auxora (zegocractin), an intravenous CRAC channel inhibitor being evaluated for acute pancreatitis and acute kidney injury, and CM5480, a next-generation oral CRAC channel inhibitor in preclinical development for chronic conditions including pulmonary arterial hypertension (PAH). The company's mechanistic thesis is a dual mode of action — modulation of immune cell activation in parallel with protection of non-immune tissue cells from calcium-driven injury — applied to indications with no approved disease-modifying therapies and high mortality or morbidity, including approximately 300,000 annual US acute pancreatitis hospitalizations and roughly 1.25 million annual US ICU cases of Stage 2/3 AKI.
The company became Nasdaq-listed (ticker: CALC) following its 2022-2023 all-stock merger with Graybug Vision, and is headquartered in La Jolla, California with 11-50 employees. CalciMedica is pre-commercial and pre-revenue; its business model relies on advancing clinical candidates toward FDA approval, after which future revenue would derive from pharmaceutical commercialization rather than current licensing or product sales. Capital formation has come through a series of private placements, a $32.5 million credit facility from Avenue Venture Opportunities Fund II, and an SEC-registered exempt offering by a subsidiary. Current operating risks include the 2025 discontinuation of the Phase 2 KOURAGE trial of Auxora in AKI due to safety concerns (subsequently allowed to proceed by FDA), a March 2026 Nasdaq delisting notice for noncompliance with minimum bid and market value requirements, and ongoing cash burn against a clinical-stage cost base.
CalciMedica firmographics
Firmographics- Name
- CalciMedica
- Legal name
- CalciMedica Inc.
- Website
- https://calcimedica.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CalciMedica is a clinical-stage biopharmaceutical company developing proprietary CRAC channel inhibitor therapies — including IV candidate Auxora and oral candidate CM5480 — for acute and chronic inflammatory, immunologic, and cardiopulmonary diseases with no approved disease-modifying treatments.
- Ownership category
- akta.pro rank
CalciMedica industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where CalciMedica is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CalciMedica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Product Development Stage: Pre-revenue clinical-stage biopharmaceutical company. Revenue expected upon regulatory approval and commercialization of Auxora or other pipeline candidates. The company has received financing through private placements and credit facilities to fund operations.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CalciMedica product offering
Product offeringCore offering
CalciMedica is a clinical-stage biopharmaceutical company developing proprietary CRAC (calcium release-activated calcium) channel inhibitor therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its lead product candidate, Auxora (zegocractin), is an intravenous small-molecule CRAC channel inhibitor being advanced in clinical trials for acute pancreatitis and acute kidney injury with respiratory failure. A second candidate, CM5480, is a next-generation oral CRAC channel inhibitor in preclinical development for chronic indications including pulmonary arterial hypertension.
Product overview
CalciMedica is a clinical-stage biopharmaceutical company developing a portfolio of CRAC (calcium release-activated calcium) channel inhibitors for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. The company's product portfolio consists of two drug candidates: Auxora, an intravenous formulation for acute conditions such as acute pancreatitis and acute kidney injury, and CM5480, an oral next-generation CRAC channel inhibitor for chronic diseases including pulmonary arterial hypertension. The company does not offer technology products or platforms.
Differentiator
Problem solved
Functional benefit
Brands
- Auxora: Intravenous formulation of the proprietary small molecule CRAC channel inhibitor zegocractin, being developed for treatment of multiple acute inflammatory and immunologic illnesses including acute pancreatitis and acute kidney injury.
- CM5480
Products and services
- Auxora (zegocractin) Auxora is an intravenous formulation of zegocractin, a proprietary small-molecule CRAC (calcium release-activated calcium) channel inhibitor being developed for the treatment of acute inflammatory and immunologic illnesses including acute pancreatitis and acute kidney injury with respiratory failure. It is intended for hospital use in critically ill patient populations with high unmet need where no approved disease-modifying therapies currently exist.
- CM5480 CM5480 is a next-generation oral CRAC channel inhibitor designed for chronic dosing in inflammatory, immunologic, and cardiopulmonary diseases. It is currently in preclinical development with a lead focus on pulmonary arterial hypertension (PAH), targeting the Orai1 pathway that is not addressed by currently approved PAH therapies.
Quantifiable outcome
- 100% relative risk reduction in new-onset severe respiratory failure (high and medium dose arms combined vs placebo)
- +6 more outcomes
Companies that use CalciMedica
Customer profileSegments3 records
Ideal customer profiles3 records
CalciMedica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CalciMedica partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered supporting and core.
- TelperiansupportingCollaboration to integrate Telperian's AI engine into analysis of clinical trial data for Auxora. The partnership aims to optimize trial analysis and support regulatory discussions for Auxora's development in inflammatory and immunologic illnesses by allowing refined targeting of patient populations and efficacy endpoints.
- Graybug Vision Inc.coreGraybug Vision Inc. and CalciMedica Inc. entered into a definitive merger agreement in November 2022 to combine in an all-stock transaction. The merged entity created a Nasdaq-listed biopharmaceutical company focused on inflammatory diseases. The transaction closed in 2023, with CalciMedica becoming the surviving public company.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
CalciMedica competitors and assessment
Company assessmentDirect peers
- Inotrem: Clinical-stage biotech developing TREM-1 inhibitor nangibotide for acute inflammatory conditions including septic shock and SIRS. Closely comparable to CalciMedica given its focus on critically ill patients with acute inflammatory disease and immunomodulatory mechanism of action.
- InflaRx: Clinical-stage biopharma developing anti-complement/anti-inflammatory therapies (e.g., vilobelimab) for severe inflammatory diseases. Comparable to CalciMedica as a small-cap clinical-stage company targeting acute and chronic inflammatory conditions with novel immunomodulatory mechanisms.
- Atox Bio: Clinical-stage company developing therapeutics for critically ill patients with severe infections and inflammatory conditions. Comparable focus on acute-care inflammation and immunomodulation targeting life-threatening hospital indications similar to Auxora.
Broad incumbents
- Mallinckrodt Pharmaceuticals: Established specialty biopharma with a portfolio of critical-care, hospital, and immunology products (and historical overlap with CalciMedica's CMO). Comparable as a broader player in acute-care and inflammatory disease therapeutics, but at far greater commercial scale.
- Bristol-Myers Squibb: Global biopharma with established immunology and cardiopulmonary franchises. Comparable as a broad incumbent in inflammation and immunology that could pursue platform M&A in the CRAC channel space.
- AbbVie: Large biopharma with a major immunology franchise (Humira, Rinvoq, Skyrizi). Comparable as a broad incumbent operating across inflammatory and immunology indications, and a plausible strategic acquirer of small-cap inflammation platforms.
Emerging players
- RedHill Biopharma: Specialty pharma focused on gastrointestinal and inflammatory diseases including acute indications. Comparable in therapeutic-area overlap (GI inflammation) and in operating as a small-cap clinical/commercial company.
- Aurinia Pharmaceuticals: Small-cap clinical/commercial biopharma focused on immune-mediated diseases including lupus nephritis. Comparable as a clinical-stage immunology player targeting serious inflammatory conditions with high unmet need, though Aurinia has reached commercialization.
- BioXcel Therapeutics: Clinical-stage biopharma using AI-driven drug development for inflammation and neuroscience indications. Comparable as a small-cap clinical-stage company using novel technology platforms to address acute inflammatory diseases.
- Applied Therapeutics: Clinical-stage biopharma developing novel therapies for serious diseases with high unmet need, with inflammation and rare-disease focus. Comparable as a small-cap clinical-stage company pursuing pivotal-stage assets in underserved indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CalciMedica social profiles
Digital presenceCalciMedica financial estimates
Financial estimateRevenue estimate
Valuation estimate
CalciMedica leadership team
Management profileNumber of profiles
Profiles10 records
CalciMedica subsidiaries and ownership
Company hierarchySubsidiaries1 record
CalciMedica funding detail
Funding detailFunding overview
Funding rounds18 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CalciMedica M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CalciMedica
What does CalciMedica do?
CalciMedica is a clinical-stage biopharmaceutical company developing proprietary CRAC (calcium release-activated calcium) channel inhibitor therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its lead product candidate, Auxora (zegocractin), is an intravenous small-molecule CRAC channel inhibitor being advanced in clinical trials for acute pancreatitis and acute kidney injury with respiratory failure. A second candidate, CM5480, is a next-generation oral CRAC channel inhibitor in preclinical development for chronic indications including pulmonary arterial hypertension.
Is CalciMedica a public or private company?
CalciMedica is a public company. It is classified as public and is currently operating.
When was CalciMedica founded?
CalciMedica was founded in 2007. It employs 11 to 50 people.
Where is CalciMedica based?
CalciMedica is headquartered in La Jolla, United States, in the North America region.
How does CalciMedica make money?
One revenue line is on record: product Development Stage.
Who are CalciMedica's main competitors?
Direct peers on record are Inotrem, InflaRx and Atox Bio. Broad incumbents are Mallinckrodt Pharmaceuticals, Bristol-Myers Squibb and AbbVie. Emerging players are RedHill Biopharma, Aurinia Pharmaceuticals, BioXcel Therapeutics and Applied Therapeutics.
Does CalciMedica have an API?
No public API is recorded for CalciMedica.
What industry is CalciMedica in?
CalciMedica's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.